Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine.

Dominique Caugant, Paul Kristiansen, Xin Wang, Leonard Mayer, Muhamed-Kheir Taha, Rasmata Ouédraogo, Denis Kandolo, Flabou Bougoudogo, Samba Sow, Laurence Bonte

To cite this version:
Dominique Caugant, Paul Kristiansen, Xin Wang, Leonard Mayer, Muhamed-Kheir Taha, et al.. Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine.. PLoS ONE, Public Library of Science, 2012, 7 (9), pp.e46019. 10.1371/journal.pone.0046019. pasteur-02085540

HAL Id: pasteur-02085540
https://hal-pasteur.archives-ouvertes.fr/pasteur-02085540
Submitted on 30 Mar 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons CCO - Public Domain Dedication| 4.0 International License
Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine

Dominique A. Caugant1,2*, Paul A. Kristiansen1, Xin Wang3, Leonard W. Mayer3, Muhamed-Kheir Taha4, Rasmata Ouédraogo5, Denis Kandolo6, Flabou Bougoudogo7, Samba Sow8, Laurence Bonte9

1 WHO Collaborating Centre for Reference and Research on Meningococci, Norwegian Institute of Public Health, Oslo, Norway, 2 Faculty of Medicine, University of Oslo, Oslo, Norway, 3 WHO Collaborating Center for Prevention and Control of Epidemic Meningitis, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 4 WHO Collaborating Centre for Reference and Research on Meningococci, Institut Pasteur, Paris, France, 5 Laboratoire de Référence Meningite, Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso, 6 WHO Inter country Support Team for West Africa, Ouagadougou, Burkina Faso, 7 Institut National de Recherche en Santé Publique (INRSP), Bamako, Mali, 8 Centre pour les Vaccins en Développement (CVD), Bamako, Mali, 9 Support Logistique, Médecins Sans Frontières, Paris, France

Abstract

Background: The serogroup A conjugate meningococcal vaccine, MenAfriVac, was introduced in mass vaccination campaigns in December 2010 in Burkina Faso, Mali and Niger. In the coming years, vaccination will be extended to other African countries at risk of epidemics. To document the molecular characteristics of disease-causing meningococcal strains circulating in the meningitis belt of Africa before vaccine introduction, the World Health Organization Collaborating Centers on Meningococci in Europe and United States established a common strain collection of 773 isolates from cases of invasive meningococcal disease collected between 2004 and 2010 from 13 sub-Saharan countries.

Methodology: All isolates were characterized by multilocus sequence typing, and 487 (62%) were also analyzed for genetic variation in the surface antigens PorA and FetaA. Antibiotic susceptibility was tested for part of the collection.

Principal Findings: Only 19 sequence types (STs) belonging to 6 clonal complexes were revealed. ST-5 clonal complex dominated with 578 (74.8%) isolates. All ST-5 complex isolates were remarkably homogeneous in their PorA (P1.20,9) and FetaA (F3-1) and characterized the serogroup A strains which have been responsible for most epidemics during this time period. Sixty-eight (8.8%) of the 773 isolates belonged to the ST-11 clonal complex which was mainly represented by serogroup W135, while an additional 38 (4.9%) W135 isolates belonged to the ST-175 complex. Forty-eight (6.2%) serogroup X isolates from West Africa belonged to the ST-181 complex, while serogroup X cases in Kenya and Uganda were caused by an unrelated clone, ST-5403. Serogroup X, ST-181, emerged in Burkina Faso before vaccine introduction.

Conclusions: In the seven years preceding introduction of a new serogroup A conjugate vaccine, serogroup A of the ST-5 clonal complex was identified as the predominant disease-causing strain.

Introduction

The meningitis belt of Africa was first described by Lapeysonnie in 1963 [1] and was further defined by Molesworth and co-workers in 2002 [2]. It now encompasses parts or the whole of 25 countries south of the Sahara, stretching from Ethiopia in the east to Senegal in the west. Every year during the dry season the region is affected by outbreaks of meningococcal meningitis and large epidemics emerge unpredictably 8 to 10 years apart. Traditionally, serogroup A meningococci have been responsible for most of the endemic disease as well as for the large epidemics, but more recently serogroup W135 and serogroup X strains have also been involved [3–13]. Emergence and dissemination of a new strain may lead to epidemics under certain environmental conditions. New strains that appeared and were disseminated during the annual Hajj pilgrimage have been linked to several epidemics [14].

The most severe epidemic of meningococcal meningitis experienced by Africa was in 1996, with more than 150,000 reported cases and 16,000 deaths [15–17]. It was caused by a serogroup A clone of Neisseria meningitidis assigned to sequence type (ST) -5 using multilocus sequence typing [18]. In 2002, Burkina Faso was the first country to experience a major serogroup W135 epidemic, with 13,000 reported cases, and 1,400 deaths [10]. A hypervirulent ST-11 clone was responsible for this epidemic [7].
Preventive vaccination with meningococcal polysaccharide vaccines was usually not attempted because of their relatively short protection and low immunogenicity in young children [19]. Thus, the World Health Organization (WHO) recommended reactive mass vaccination to halt epidemics using either the A/C or the A/C/W135 polysaccharide vaccines, depending on the serogroup of the outbreak strains [20].

Starting in 2002, the Meningitis Vaccine Project (MVP), a public-private partnership between WHO and the Program for Appropriate Technology in Health (PATH), developed an effective monovalent serogroup A conjugate meningococcal vaccine, MenAfriVac, at a price affordable for African countries, with the aim of eliminating the devastating serogroup A epidemics occurring in sub-Saharan Africa [21]. The vaccine was introduced in a country-wide mass vaccination campaign in Burkina Faso in December 2010, where the vaccine was offered to all individuals aged 1 to 29 years. Vaccination of the same age group started in Mali and Niger in 2010 and was completed in 2011 [22].

In 2005 the two WHO Collaborating Centers for Reference and Research on Meningococci in Marseille, France, and Oslo, Norway, published an overview on the phenotypic and genotypic features of meningococcal isolates recovered from meningitis cases between 1988 and 2003 in 13 countries of the African meningitis belt [18]. We report here the molecular characteristics of the strains circulating in these countries from 2004 to 2010, prior to MenAfriVac introduction. The strain collection established by these two WHO Collaborating Centers was supplemented with isolates received by the WHO Collaborating Center for Prevention and Control of Epidemic Meningitis, Centers for Disease Control and Prevention, Atlanta, GA, and by the Institut Pasteur, Paris, France, which is a newly nominated WHO Collaborating Center, following closure of the WHO Center in Marseille in 2010.

Materials and Methods

Bacterial isolates

The strain collection comprised a total of 773 isolates, all recovered from cerebrospinal fluid samples from patients of countries of the African meningitis belt and forwarded to the WHO Collaborating Centres. Strains from patients in other African countries were excluded, as were isolates from asymptomatotic carriers. The sources of the isolates were as follows: 1) a total of 372 isolates from 2004 to 2009 constituted a large part (88%) of the collection of invasive isolates from the WHO Collaborating Centre in Marseille for that period; the isolates were transferred to the other WHO Collaborating Centres under contract for scientific purposes; 2) 360 isolates were from the WHO Collaborating Centre in Oslo. These were assembled either by physicians working for Médecins Sans Frontières, using Trans-Trans-mail database [23] to collect samples in areas where meningitis outbreaks were occurring; during field evaluations performed by the WHO Inter-country Support Team, Ouagadougou; or directly by the co-authors; 3) the remaining isolates were sent to the WHO Collaborating Centre by co-authors. Bacterial identification was determined by Gram staining, the oxidase reaction, and standard biochemical tests. The strains were stored at −80°C in brain heart broth with 15% sterile glycerol or in Greaves solution [24].

Serogrouping

*N. meningitidis* strains were serogrouped by slide agglutination with sera manufactured by the Institut de Médecine Tropicale du Service de Santé des Armées, Marseilles, France, or commercial antisera (Remel, GA, USA).

Antimicrobial sensitivity testing

Antimicrobial susceptibility testing was performed by determination of the minimal inhibitory concentrations (MIC) using Etest (AB Biodisk, Solna, Sweden). Isolates were tested for susceptibility to penicillin G, amoxicillin, ceftriaxone, ciprofloxacin, chloramphenicol, rifampin, tetracycline and sulphonamides, and classified using the breakpoints from the European Committee on Antimicrobial Susceptibility Testing (http://www.eucast.org/).

Genotypic characterization

DNA from each strain was prepared by suspending bacteria in Tris-EDTA buffer (10 mM Tris-HCl and 1 mM EDTA), pH 8.0, heating at 95°C for 10 min, and followed by centrifugation at 16,000× g for 5 min. The supernatant was used as DNA template for PCR. After DNA amplification by PCR, sequence of fragments from the seven housekeeping genes, *abcZ* (putative ABC transporter), *adk* (adenylate kinase), *araE* (shikimate dehydrogenase), *fumC* (fumarase), *gdh* (glucose-6-phosphate dehydrogenase), *pdhC* (pyruvate dehydrogenase subunit), and *pgm* (phosphoglucomutase), were analysed on an AB Prism 373, AB Prism 377 or AB 3130XL DNA sequencer (Applied Biosystems, Foster City, CA), according to the method on the MLST website (http://pubmlst.org/neisseria/). The DNA sequences were compared with the existing alleles on the MLST website using sequence query or the meningococcal genome informatics platform (MGIP) for determination of the allele numbers, STs, and clonal complexes of the isolates [25].

Variation in the *porA* and *fetA* genes, coding for the outer membrane proteins PorA and FetA, respectively, was determined by DNA sequencing, as described previously [26,27]. New MLST alleles and STs were submitted to the MLST database (http://pubmlst.org/neisseria/), together with the strain serogroup and *porA* and *fetA* sequences.

PCR analysis of the genes coding for the polysaccharide capsule was performed for genogroup determination of non-serogroupable isolates as described [28].

Data analyses

All the data were entered into an Excel database (Microsoft Corporation, Redmond, WA) and analysed using R version 2.10.0 [29].

Results

Origin of isolates

The isolates analysed by MLST originated from Benin (n = 12), Burkina Faso (n = 285), Cameroon (n = 24), Central African Republic (CAR) (n = 5), Chad (n = 53), Ghana (n = 6), Kenya (n = 3), Mali (n = 132), Niger (n = 124), Nigeria (n = 57), Sudan (n = 22), Togo (n = 29) and Uganda (n = 21). The number of isolates retrieved by country and year varied greatly, ranging from zero for some countries in some years to 128 from Burkina Faso in 2006 (Table 1). For Burkina Faso, Chad, Mali and Niger, meningococcal isolates were obtained and characterized for at least 6 of the 7 years of the period analysed.

Serogroups

Of the 773 isolates, 568 (73.5%) were serogroup A, 105 (13.6%) serogroup W135, 63 (8.2%) serogroup X, 22 (2.8%) serogroup Y and 15 (1.9%) were non-groupable (NG). Serogroup W135 was present in all these 13 countries within the meningitis belt, while serogroup A was recovered from all countries except Kenya. Serogroup X was mainly found in Niger, Burkina Faso and Uganda. Burkina Faso was the only country where all the
| Year | Serogroup | Clonal complex | ST | No. of strains (yearly %) | Country source (no. of isolates) |
|------|-----------|----------------|----|----------------------------|----------------------------------|
| 2004 | A         | 5              | 7  | 23 (32.4)                 | Benin (1); CAR (4); Ghana (4); Nigeria (13); Niger (1) |
|      | A         | 5              | 2859 | 17 (23.9)              | Burkina Faso (16); Mali (1); |
|      | W135      | 11             | 11  | 11 (15.5)                 | Benin (1); Burkina Faso (8); Ghana (2) |
|      | W135      | 23             | 4375 | 1 (1.4)                 | Burkina Faso (1); |
|      | W135      | 175            | 2881 | 3 (4.2)                 | Benin (1); Chad (1); Nigeria (1) |
|      | X         | 181            | 181  | 3 (4.2)                 | Niger (3) |
|      | Y         | 11             | 11  | 1 (1.4)                 | Burkina Faso (1) |
|      | Y         | 23             | 4375 | 1 (1.4)                 | Burkina Faso (1) |
|      | Y         | 167            | 767  | 1 (1.4)                 | Benin (1) |
|      | NG⁰       | 5              | 2859 | 7 (9.9)                 | Burkina Faso (6); Mali (1) |
|      | NG        | 23             | 4375 | 2 (2.8)                 | Burkina Faso (2) |
|      | NG UA³    | 192            | 192  | 1 (1.4)                 | Burkina Faso (1) |
| 2005 | W135      | 11             | 11  | 6 (35.3)                 | Chad (4); Kenya (2) |
|      | W135      | 175            | 2881 | 4 (23.5)                | Niger (4) |
|      | X         | 181            | 181  | 7 (41.2)                 | Niger (7) |
|      | A         | 5              | 7   | 36 (16.0)                | Burkina Faso (1); Mali (1); Niger (25); Nigeria (3); Sudan (6) |
|      | A         | 5              | 2859 | 126 (56.0)              | Burkina Faso (122); Mali (4) |
|      | A         | 5              | 5788 | 1 (0.4)                 | Niger (1) |
|      | W135      | 11             | 11  | 14 (6.2)                 | Chad (1); Mali (5); Sudan (3); Uganda (5) |
|      | W135      | 11             | 5779 | 1 (0.4)                 | Burkina Faso (1) |
|      | W135      | 175            | 2881 | 5 (2.2)                 | Benin (3); Niger (2) |
|      | X         | 181            | 181  | 23 (10.2)                | Niger (23) |
|      | X         | 181            | 5789 | 1 (0.4)                 | Niger (2) |
|      | X         | UA             | 5403 | 9 (4.0)                 | Kenya (1); Uganda (8) |
|      | Y         | 167            | 2953 | 1 (0.4)                 | Benin (1) |
|      | Y         | 23             | 4375 | 5 (2.2)                 | Burkina Faso (4); Niger (1) |
|      | Y         | 167            | 767  | 2 (0.9)                 | Mali (2) |
| 2007 | A         | 5              | 7   | 34 (18.6)                | Chad (4); Mali (3); Niger (12); Nigeria (3); Sudan (12) |
|      | A         | 5              | 2859 | 113 (61.7)              | Burkina Faso (71); Mali (23); Togo (19) |
|      | W135      | 11             | 11  | 8 (4.4)                 | Mali (8) |
|      | W135      | 175            | 2881 | 8 (4.4)                 | Benin (1); Chad (1); Togo (6) |
|      | X         | 181            | 181  | 3 (1.6)                 | Burkina Faso (3) |
|      | X         | UA             | 5403 | 6 (3.3)                 | Uganda (6) |
|      | Y         | 23             | 4375 | 1 (0.5)                 | Burkina Faso (1) |
|      | Y         | 167            | 767  | 4 (2.2)                 | Mali (4) |
|      | Y         | 167            | 2880 | 1 (0.5)                 | Burkina Faso (1) |
|      | Y         | 167            | 8620 | 1 (0.5)                 | Mali (1) |
|      | Y         | UA             | 192  | 1 (0.5)                 | Mali (1) |
|      | NG        | 5              | 2859 | 2 (1.1)                 | Burkina Faso (1); Mali (1) |
|      | NG UA³    | 192            | 192  | 1 (0.5)                 | Burkina Faso (1) |
| 2008 | A         | 5              | 7   | 18 (16.8)                | Mali (3); Niger (7); Nigeria (7); Sudan (1) |
|      | A         | 5              | 2859 | 62 (57.9)               | Burkina Faso (24); Mali (36); Niger (2) |
|      | A         | 5              | 6968 | 1 (0.9)                 | Burkina Faso (1) |
|      | W135      | 11             | 11  | 5 (4.7)                 | Cameroon (1); CAR (1); Chad (3) |
|      | W135      | 175            | 2881 | 13 (12.1)               | Benin (1); Burkina Faso (1); Cameroon (9); Togo (2) |
|      | X         | 181            | 181  | 3 (2.8)                 | Benin (1); Togo (2) |
|      | Y         | 23             | 4375 | 1 (0.9)                 | Burkina Faso (1) |
|      | Y         | 167            | 767  | 2 (1.9)                 | Benin (1); Mali (1) |
|      | NG        | 5              | 2859 | 1 (0.9)                 | Mali (1) |
serogroup isolates. No serogroup B or C isolate was recovered from any of the countries.

Genogrouping was performed on the 11 of the 15 NG isolates that were still available. The genes for serogroup A and serogroup Y capsule were detected in 5 and 2 isolates, respectively, but no PCR product was obtained with any of the primer sets for the remaining 4 isolates.

Antibiotic susceptibility

Antimicrobial susceptibility testing was performed for a selection of isolates (Table 2). All isolates tested were susceptible to amoxicillin, ceftriaxone, ciprofloxacin, chloramphenicol and rifampin. Of the 336 isolates tested against sulphonamide, all but 9 were resistant; the exceptions were 8 serogroup X isolates from Burkina Faso and a serogroup W135 isolate from Kenya. Among the isolates tested against tetracycline, all serogroup A strains were resistant while all the serogroup W135 and X isolates were susceptible. Reduced susceptibility to penicillin was seen for 9% of the isolates, but there was no association with the serogroup of the strains.

Molecular characterisation

The ST-5 clonal complex dominated the strain collection with 578 isolates (74.8%), followed by 68 (8.8%) isolates of ST-11 complex, 48 (6.2%) isolates of ST-181 complex, 38 (4.9%) isolates of ST-175 complex, 12 (1.6%) isolates of ST-23 complex and 11 (1.4%) isolates of ST-167 complex (Table 3). The remaining 18 isolates belong to a ST that cannot be assigned to any ST complex; ST-192 (3 isolates) and ST-5403 (15 isolates).

The ST-5 complex was composed of 368 (63.7%) ST-2859 isolates, 207 (35.8%) ST-7 isolates, as well as one isolate (0.2%) of each of the STs 6968, 5788 and 8639. The isolates of the ST-5 complex were either serogroup A (568 isolates) or NG (10 isolates) and a total of 344 ST-5 complex isolates that were further subtyped had identical PorA (P1.20,9) and FetA (F3-1). All serogroup A isolates belonged to the ST-5 complex.

The ST-11 clonal complex included 66 (97%) ST-11 isolates and two SLVs of ST-11, ST-5779 and ST-8637, both with one isolate each. The ST-11 complex was mainly composed of serogroup W135 isolates (97%). All 53 W135 ST-11 complex isolates for which PorA was sequenced were P1.5,2. FetA variant

### Table 2. Antibiotic susceptibility of invasive meningococcal isolates from sub-Saharan Africa in 2004–2010.

| Antibiotic  | No. of isolates tested | MIC range (μg/ml) | % of isolates |
|-------------|------------------------|------------------|--------------|
|             |                        | Susceptible | Intermediate | Resistant    |
| Penicillin G| 526                    | 0.012–0.64    | 91           | 7            | 2            |
| Amoxicillin | 189                    | 0.012–0.19    | 100          | 0            | 0            |
| Ceftriaxone | 364                    | 0.001–0.004   | 100          | 0            | 0            |
| Ciprofloxacin| 336                   | 0.003–0.008   | 100          | 0            | 0            |
| Chloramphenicol| 526                  | 0.38–2       | 100          | 0            | 0            |
| Rifampin    | 508                    | 0.002–0.25    | 100          | 0            | 0            |
| Tetracycline| 169                    | 0.125–8      | 20           | 0            | 80           |
| Sulphonamide| 336                   | 0.025–1024   | 2            | 0            | 98           |
F1-1 dominated within the ST-11 complex with 92.7% of sequenced isolates.

The other clonal complex associated with serogroup W135 was the ST-115 complex, with 37 isolates (97.4%) of ST-2081 and one isolate of ST-8638, a SLV of ST-2081 identified in Burkina Faso in 2010. The dominant PorA-FetA combination among the 20 isolate of ST-8638, a SLV of ST-2881 identified in Burkina Faso in 2006. All these isolates were serogroup A.

Table 3. Distribution of lineages found among 773 N. meningitidis strains isolated in the African meningitis belt between 2004 and 2010.

| Clonal complex | ST   | Serogroup | No. (%) of isolates |
|----------------|------|-----------|---------------------|
| ST-15          | 2859 | A         | 207 (26.8%)         |
|                | 5788 | A         | 16 (2.1%)           |
|                | 6968 | A         | 1 (0.13%)           |
|                | 8639 | A         | 1 (0.13%)           |
| ST-11          | 11   | NG        | 1 (0.13%)           |
|                | 5779 | W135      | 64 (8.28%)          |
|                | 8637 | W135      | 1 (0.13%)           |
| ST-23          | 2953 | Y         | 1 (0.13%)           |
|                | 4375 | NG        | 4 (0.53%)           |
|                | 5779 | W135      | 1 (0.13%)           |
|                | 8637 | W135      | 1 (0.13%)           |
| ST-167         | 767  | Y         | 9 (1.17%)           |
|                | 2880 | Y         | 1 (0.13%)           |
|                | 8620 | Y         | 1 (0.13%)           |
| ST-175         | 2881 | W135      | 37 (4.79%)          |
|                | 8638 | W135      | 1 (0.13%)           |
| ST-181         | 181  | X         | 46 (5.95%)          |
|                | 5789 | X         | 2 (0.26%)           |
| UA*            | 192  | NG        | 2 (0.26%)           |
|                | 5403 | X         | 1 (0.13%)           |

*NG, Non-groupable as determined by slide agglutination method.
UA, Unassigned to any clonal complex.

This study included 773 isolates recovered from meningococcal disease cases in 13 countries of the meningitis belt during a 7-year period. Only 19 distinct STs were revealed. These STs belonged to 6 clonal complexes, two of which, the ST-5 and the ST-11 complexes, accounted for 83.6% of the isolates.

Evolution of ST-5 complex
Since the introduction of the ST-5 complex in the meningitis belt in 1987 [9], variation in housekeeping genes has occurred, resulting in new STs (Fig. 2). In the period 2004–2010, ST-7, which had already totally replaced ST-5 in the meningitis belt by 2003 [18], and ST-2859, which emerged in Burkina Faso in 2003, dominated within the ST-5 complex. In addition, three new STs emerged during the period 2004–2010: ST-6968, a single locus variant (SLV) of ST-2859 in the pdhC locus was first identified in Burkina Faso in 2008; ST-5788 and ST-8639 were first identified in Niger in 2006 and Mali in 2010, respectively, and are SLVs of ST-7, in the arsE and pdhC loci, respectively. In contrast, no variation in the genes coding for the surface exposed outer membrane proteins PorA and FetA has been detected.

Discussion
This study included 773 isolates recovered from meningococcal disease cases in 13 countries of the meningitis belt during a 7-year period. Only 19 distinct STs were revealed. These STs belonged to 6 clonal complexes, two of which, the ST-5 and the ST-11 complexes, accounted for 83.6% of the isolates.

Limitation of the study
In the period 2004 to 2010 approximately 225,000 meningitis cases from 12 countries within the African meningitis belt were reported by the WHO Inter country Support Team – West Africa, which compiles information from most countries of the sub-Saharan Africa [30]. This is summarized in Table 4 which showed a relatively quiet year in 2005 with less than 7,000 reported cases to the peak year of 2009 with nearly 80,000 reported cases. Of the reported meningitis cases less than 10% have a clinical specimen taken and examined microbiologically in the country of origin. Meningococcal meningitis was laboratory-confirmed for 7803 patients, i.e. about for one third of the patients from whom a clinical sample was analysed.
Figure 1. Serogroup distribution (%) in Burkina Faso, Mali and Niger in the period 2004–2010. In the figure, the few non-groupable isolates were included together with those assigned to a serogroup on the basis of the capsule PCR and/or their molecular profile, except for ST-192 isolates (n = 2) that were likely to harbour a capsule null gene [36]. Black bars: serogroup A; white bars: serogroup W135; oblique strips: serogroup X; vertical strips: serogroup Y.

doi:10.1371/journal.pone.0046019.g001
We here report the molecular characterization of 773 isolates collected over this 7-year period. In our previous study, encompassing a period of 15 years, data on a total of 357 isolates had been collected [18]. This shows an overall improvement likely resulting from a better use of the laboratory in meningitis diagnosis in Africa and an increase networking of the WHO Collaborating Centers. However, in comparison to the huge number of cases occurring in the region, only a very small fraction of cases were represented in our analysis. Relating to the data collated by the WHO Inter country Support Team – West Africa the proportion of culture-confirmed meningococcal cases included in our study ranged from 4.2% in 2009 to 27.2% in 2007 (Table 4). The representation of the different countries was variable; especially we were unable to obtain strains from the Ivory Coast and Ethiopia. From these two countries, however, only 32 and 51 cases, respectively, have been culture-confirmed in this 7-year period according to reported data [30]. From the remaining countries of the meningitis belt that report to the WHO Inter country Support Team – West Africa, our collection included from 2.5% of the laboratory-confirmed cases from Niger (124 of 5061 cases) and up to 70.6% of the laboratory-confirmed cases from Mali (132 of 187 cases). These data illustrate the great differences both in surveillance systems and laboratory-based diagnosis of meningococcal meningitis between countries of the belt.

Comparing our results for the 3 countries with most isolates (Fig. 1) with the serogroup distribution reported in the WHO Meningitis Weekly Bulletin, we see however similar proportions and trends [30]. In Burkina Faso, 1,090 meningitis cases were

![Figure 2. Evolution of the ST-5 complex in the meningitis belt in the period 1988–2010.](https://doi.org/10.1371/journal.pone.0046019.g002)

**Table 4.** Number (%) of studied isolates in relation to the number of laboratory-confirmed cases and number of reported cases per year in countries of the meningitis belt.

| Year | No. of reported cases | No. of CSF samples analysed | No. of laboratory-confirmed MD cases | No. of isolates in the study (%) |
|------|-----------------------|----------------------------|-------------------------------------|----------------------------------|
| 2004 | 31,712                | NA*                        | 809                                 | 71 (8.8)                         |
| 2005 | 9,876                 | 1,193                      | 190                                 | 17 (8.9)                         |
| 2006 | 41,526                | 6,215                      | 1,572                               | 225 (14.3)                       |
| 2007 | 45,997                | 2,533                      | 680                                 | 183 (26.9)                       |
| 2008 | 33,381                | 3,413                      | 1,134                               | 107 (9.4)                        |
| 2009 | 88,199                | 5,688                      | 2,210                               | 92 (4.2)                         |
| 2010 | 30,103                | 4,132                      | 1,238                               | 78 (6.3)                         |

Data source WHO Inter country Support Team – WestAfrica [30]. Numbers from the Democratic Republic of Congo have been removed to include only countries of the meningitis belt.

*NA, Information not available.

doi:10.1371/journal.pone.0046019.t004
study. During the 7-year period analysed here, Niger experienced a serogroup X outbreak in 2006 [3]. Serogroup X, however, declined later on in Niger and represented less than 1% of the isolates in 2010 [4]. Delrieu and coworkers reported a serogroup X outbreak in one district in Togo in 2007 [35]. Although no isolates had been stored, MLST on cerebrospinal samples revealed ST-181 [35]. This serogroup X strain was present in Burkina Faso in a small fraction (4%) of the cases in 2007, but emerged as an important cause of disease in 2010 where it was identified in 7 of 10 meningococcal isolates (1.05%). The circulation of serogroup X meningococci among asymptomatic carriers and the high incidence of serogroup X disease before MenAfriVac introduction should be kept in mind when evaluating possible serogroup replacement following use of the vaccine. The possible spread of serogroup X has to be closely monitored in the coming years as there are yet no available vaccines against this serogroup.

Interestingly, serogroup X meningococcal disease also emerged in Kenya and in Uganda in 2006, but these cases were caused by a strain unrelated to the ST-181 complex [8].

Conclusions
Our data show that before introduction of MenAfriVac in the African meningitis belt, serogroup A N. meningitidis of the ST-5

Continuous spread of serogroup W135
The first large epidemic caused by serogroup W135, ST-11, occurred in Burkina Faso in 2002, probably following amplification of this clone after the annual Hajj pilgrimages of 2000 and 2001 [7,33]. Prior to the Burkina Faso epidemic, serogroup W135 ST-11 isolates had been identified in Chad in 1996, Cameroon and Senegal in 2000, CAR in 2001, showing a large dispersal of the clone in the meningitis belt [19]. In the period 2004–2010, the ST-11 complex was identified in all the countries of the meningitis belt where isolates were obtained, except for Niger and Togo. While ST-11 complex was present in Niger in 2002 and 2003, from 2004 the W135 isolates recovered from that country belonged to ST-2881 of the ST-175 complex. In 2010, W135 predominated in Niger [30], but no isolates were available to us. Laboratory identification of the etiological agent was mainly performed by PCR, but all 9 W135 isolates tested by Collard and co-workers [4] belonged to ST-11. The ST-11 complex seemed to disappear also from Burkina Faso after 2006 and the few W135 recovered then belonged to the ST-175 complex. In Chad, serogroup W135 ST-11 dominated during most of the period 2004–2010, belonging either to ST-11 (2005, 2006, 2008–2010) or ST-2881 (2004 and 2007). In the years 2008–2010, the proportion of serogroup W135 in Chad decreased while the proportion of serogroup A increased (Fig. 1). In Niger, isolates of serogroup W135 belonging to ST-11 accounted for nearly 50% of the case isolates in 2010 [4]. In contrast to the ST-11 complex, the ST-175 complex has not been associated with major epidemics and is responsible for endemic disease cases. This clonal complex is geographically widespread and has been identified in meningococcal carriage studies in Europe and Asia (http://pubmlst.org/neisseria/).

Emergence of serogroup X
Carriage and sporadic disease-associated serogroup X isolates have been detected in the meningitis belt as early as in the 1990s [6,8,34]. During the 7-year period analysed here, Niger experienced a serogroup X outbreak in 2006 [3] and the responsible epidemic strain was ST-181 (Table 1). Serogroup X, however, declined later on in Niger and represented less than 1% of the isolates in 2010 [4]. Delrieu and coworkers reported a serogroup X outbreak in one district in Togo in 2007 [35]. Although no isolates had been stored, MLST on cerebrospinal samples revealed ST-181 [35]. This serogroup X strain was present in Burkina Faso in a small fraction (4%) of the cases in 2007, but emerged as an important cause of disease in 2010 where it was identified in 7 of our 10 meningococcal isolates. Serogroup X outbreaks occurring in northern and central regions of Burkina Faso in 2010 have been documented [35]. In 2009, serogroup X ST-181 had been identified in 0.44% of healthy carriers in Burkina Faso [28], with a higher prevalence in the north-east district of Kaya, close to Niger (1.05%). The circulation of serogroup X meningococci among asymptomatic carriers and the high incidence of serogroup X disease before MenAfriVac introduction should be kept in mind when evaluating possible serogroup replacement following use of the vaccine. The possible spread of serogroup X has to be closely monitored in the coming years as there are yet no available vaccines against this serogroup.

Interestingly, serogroup X meningococcal disease also emerged in Kenya and in Uganda in 2006, but these cases were caused by a strain unrelated to the ST-181 complex [8].

Conclusions
Our data show that before introduction of MenAfriVac in the African meningitis belt, serogroup A N. meningitidis of the ST-5

Laboratory-confirmed in-country for the 7-year period. The great majority of isolates were serogroup A, except for 2004 and 2010 when a mixed situation was seen. In 2004, the second serogroup was W135, while in 2010 serogroup X emerged toward the end of the season; these situations were evidenced both by the in-country surveillance and our strain collection.

Serogroup A dominated in Mali during the entire period. The mixed population we described in 2006 and 2007 was not evident from the WHO Meningitis Weekly Bulletin, where a few non-A cases were laboratory-confirmed (1 of 36 in 2006 and 5 of 60 in 2007) [30].

In Niger the National Reference Laboratory (CERMES) in Niamey provides a remarkable example of what kind of laboratory support can be achieved in West Africa. More than one thousand meningococcal meningitis cases have been confirmed and serogrouped during the most severe epidemic years of 2006 and 2009. The representativeness of the small fraction of isolates from Niger examined in this work is shown by the gradual increase in serogroup X until 2006, followed by a new wave of serogroup A cases in 2009.

For the other countries data are sporadic and our strain collection can only show which clonal complex and specific variant has been responsible for specific outbreaks.

Dominance of serogroup A
Serogroup A N. meningitidis was responsible for most of the meningococcal outbreaks in 2004–2010, as it was for the period 1988–2003 [18]. The genetic diversity of serogroup A strains was low as all 568 isolates belonged to only five closely related STs of the ST-5 complex and all 344 isolates analyzed for PorA and FetA were P1.20,9/F3-1. Interestingly, this porA-fetA sequence combination has been stable among the serogroup A strains that cause disease in the meningitis belt for more than two decades, which suggests that the immunologic selection pressure on these outer membrane proteins is low. This is in contrast to the high variability identified in the genes coding for these two potential vaccine antigens among serogroup B isolates [31,32]. Serogroup A strains of the ST-5 complex from other geographical areas may also harbour the P1.20,9/F3-1 antigen combination, but variants, especially for FetA, are not uncommon (http://pubmlst.org/neisseria/). This observation should be considered when developing strategies for protein-based vaccines for Africa.

Indeed, SLVs and double locus variants were detected among serogroup A isolates belonging to the ST-5 complex, and some of them (ST-7 and ST-2859) were clearly successful in successive clonal replacement within the complex. This study confirms complete replacement of ST-5 with ST-7 that occurred after 2001 [18], as none of the strains from the period 2004–2010 were ST-5. However, during this period ST-2859 which was first discovered in Burkina Faso in 2005 completely replaced ST-7 in that country. No serogroup A isolates recovered from Burkina Faso since 2005 were ST-7. The total replacement of ST-7 by ST-2859 in Burkina Faso was also evidenced in a carriage study performed in 2009 when ST-2859 was identified as the only serogroup A clone circulating among healthy carriers [28]. ST-2859 has spread from Burkina Faso to Mali in 2004 and to Niger in 2008. In these two countries, however, replacement of ST-7 by ST-2859 has not been complete, as both clones were still recovered in Niger in 2009 and in Mali in 2010. ST-2859 has not been observed in the other countries of the meningitis belt. The severe epidemic in Nigeria in 2009 (more than 56,000 reported cases) was caused by ST-7.
complex remains the predominant disease-causing clonal complex, with two STs (ST-7 and ST-2059) contributing to severe outbreaks in different countries. The situation, however, is heterogeneous both temporally and geographically. After the emergence of serogroup X ST-181 complex in Niger in 2006, the clone became a significant cause of disease in Burkina Faso in 2010 before vaccine introduction. Improved laboratory confirmation of meningitis cases is essential to assess changes in the disease epidemiology. Culture of the disease-causing organism and their population dynamics are necessary to a better understanding of the bacterial population dynamics.

Acknowledgments

This study is based in part on the strain collection assembled by Pierre Nicolas at the French Forces Institute of Tropical Medicine, Le Phare, Marseille, France. Upon Pierre’s retirement in 2010 large parts of Le Phare’s strain collection were transferred to the WHO Collaborating Centres in Oslo, Atlanta and Paris. We are greatly indebted to Pierre Nicolas and all colleagues who have contributed to that strain collection. We have been unable to get into contact with Dr. Nicolas after his retirement, and thus, we cannot acknowledge by names the contributors to his strain collection. We greatly apologize for this.

The excellent technical assistance of Torill Alvestad, Anne Marie Klem, Jan Oknes, Jeni Vuong, Raydell Anderson, Stephanie Schwartz and Eva Hong is acknowledged.

This publication made use of the Neisseria Multi Locus Sequence Typing website (http://pubmlst.org/neisseria/) sited at the University of Oxford.

Author Contributions

Conceived and designed the experiments: DAC LWM MKT. Performed the experiments: RO DK FB SS LB. Analyzed the data: PAK XW. Contributed reagents/materials/analysis tools: RO DK FB SS LB. Wrote the paper: DAC PAK XW.

References

1. Lapeyssonie L (1963) La meningite cerebrospinale en Afrique. Bull World Health Organ 28 (Suppl): 3–114.

2. Moleworth AM, Thomson MC, Connor SJ, Cresswell MP, Morse AP, et al. (2002) Where is the Meningitis Belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 96: 242–249.

3. Boisier P, Nicolas P, Djibo S, Taha M-K, Jeanne I, et al. (2007) Meningococcal meningitis: Unprecedented incidence of serogroup W135-related cases in 2006 in Niger. Clin Infect Dis 44: 657–663.

4. Collard JM, Mamou N, N’Zokou C, Faye J, Djibo S, Nicolas P, et al. (2010) Increase in serogroup X meningococcal serogroup W135, Niger, 2010. Emerg Infect Dis 16: 1496–1499.

5. Denis F, Rey JL, Amadou A, Salou P, Prince-David M, et al. (1982) Emergence of meningococcal meningitis caused by W 135 subspecies in Africa. Lancet 2: 1135–1136.

6. Djibo S, Nicolas P, Alouette JM, Djibo A, Coutur E, et al. (2003) Outbreaks of serogroup X meningococcal meningitis in Niger 1995–2000. Trop Med Int Health 8: 1118–1123.

7. Koumare B, Ouedraogo-Traore R, Sanou I, Yada AA, Sow I, et al. (2007) The first epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 25: A17–A11.

8. Matar S, Cox HS, Isakidis P, Barami B, Ogando T, et al. (2007) Serogroup X in meningococcal disease, Western Kenya. Emerg Infect Dis 13: 944–945.

9. Maye DV, Huestis MW, Ali-Hamdan N, Naschi CT, Taha MK, et al. (2002) Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J Infect Dis 185: 1596–1603.

10. Niakar A, Row AM, Legros D, Tiendrebeogo SR, Bachy C, et al. (2007) Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis 13: 920–923.

11. Nicolas P, Djibo S, Sidikou F, Tenebray B, Sarr R, et al. (2006) Epidemics caused by group X meningococcal meningitis in Africa in 2006. Med Trop 66: 494.

12. Pollard AJ, Santamarina M, Maiden MJC, Nicolas P, Handford S, et al. (2003) Meningococcal Disease in Africa. Emerg Infect Dis 9: 1503–1504.

13. Taha M-K, Do Chatelet IP, Schlumberger M, Sanou I, Djibo S, et al. (2002) Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 40: 1083–1084.

14. Greenwood B (1999) Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 93: 341–353.

15. Tikhonov E, Santamarina M, Esteves K (1997) Meningococcal disease: Public health burden and control. World Health Stat Q 50: 170–177.

16. Nicolas P, Chippaux JP, Martet G (1996) Epidemic of meningococcal meningitis in Africa in 1996: current data. Med Trop (Mars) 56: 203–204.

17. Riu J-Y, Djibo S, Sangare L, Lombart J-P, Fagot P, et al. (1996) A predictable comeback: The second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995. Bull World Health Organ 74: 1996–1981.

18. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA (2005) Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1980 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 43: 5129–5135.

19. Reingold AL, Broome CV, Hightower AW (1985) Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1: 114–118.

20. World Health Organization (2000) Detecting meningococcal meningitis epidemics in highly-endemic African countries. Wkly Epidemiol Rec 75: 306–309.

21. LaForce FM, Konde K, Viviani S, Preziosi MP (2007) The Meningitis Vaccine Project. Vaccine 25: A97–A100.

22. LaForce FM, Okwo-Bele JM (2011) Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 30: 1049–1057.

23. Ajello GW, Feeley JC, Hayes PS, Reingold AL, Bolan G, et al. (1984) Trans-isolate medium: a new medium for primary culturing and transport of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. J Clin Microbiol 20:55–58.

24. Craven DE, Frasch CE, Robbins JB (1978) Serogroup identification of Neisseria meningitidis. J Clin Microbiol 7: 410–414.

25. Katz LS, Bolen CR, Harcourt BH, Schmink S, Wang X, et al. (2009) Meningococcus genome informatics platform: A system for analyzing multilocus sequence typing data. Nucleic Acids Res 37: W606–W611.

26. Russell JE, Jolley KA, Feavers IM, Maiden MJC, Suker J (2004) PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 10: 674–678.

27. Thompson EA, Feavers IM, Maiden MJC (2003) Antigenic diversity of meningococcal enterobactin receptor FexA, a vaccine component. Microbiology 149: 1849–1858.

28. Kristiansen PA, Diomande F, Wei SC, Ouedraogo R, Sangare L, et al. (2011) Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 18: 1049–1058.

29. Graven DE, Frasch CE, Robbins JB (1978) Serogroup identification of Neisseria meningitidis. J Clin Microbiol 7: 410–414.

30. WHO Website. Available: http://www.who.int/csr/disease/meningococcal/epidemiological/en/index.html. Accessed 2012 July 4.

31. Shukla I, Raghunathan PL, Jones JD, Tiendrebeogo SR, Sanou I, Sangare L, et al. (2006) Neisseria meningitidis serogroup A antigens and the quest for a broadly cross-protective vaccine. Expert Rev Vaccines 9: 1203–1217.

32. Jolley KA, Berhony C, Maiden MJC (2007) Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev 31: 89–96.

33. Kristiansen PA, Diomande F, Wei SC, Ouedraogo R, Sangare L, et al. (2011) Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 18: 435–445.

34. Delrieu I, Yaro S, Tamekloe´ TSA, Njanpop-Lafourcade B-M, Tall H, et al. (2011) Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS ONE 6: e19513.

35. Findlow H, Vogel U, Mueller JE, Curry A, Njanpop-Lafourcade B-M, et al. (2007) Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso. J Infect Dis 195:1071–1077.